NORD and 84 organizations urge Senate HELP leadership to incorporate the RARE Act into the FDA Safety and Landmarks Advancement Act
Published: Jun 3, 2022
Tagged in: RARE Act, Orphan Drug Act, Protecting FDA Standards for Safe and Effective Drugs
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD and 84 organizations urge Senate HELP leadership to incorporate the RARE Act into the FDA Safety and Landmarks Advancement Act
Published: Jun 3, 2022
Tagged in: RARE Act, Orphan Drug Act, Protecting FDA Standards for Safe and Effective Drugs
NORD drafts comments on Senate Health, Education, Labor and Pensions committee’s discussion on FDA Safety and Landmark Advancements Act
Published: May 22, 2022
Tagged in: FDA’s Accelerated Approval Pathway, Expanded Access, Orphan Drug Act
NORD and 86 other organizations oppose the Senate including changes to the Orphan Drug Tax Credit in the Build Back Better Act
Published: Sep 21, 2021
Tagged in: Research, Access to Innovative Medicines and Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act, Orphan Drug Tax Credit
NORD and 86 other organizations ask for the removal of provisions related to the Orphan Drug Tax Credit in the House version of the Build Back Better Act
Published: Sep 21, 2021
Tagged in: Research, Access to Innovative Medicines and Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act, Orphan Drug Tax Credit
NORD letter to House Ways & Means Committee opposing Section 138141 of the Build Back Better Act
Published: Sep 13, 2021
Tagged in: Access to Innovative Medicines and Therapies, Orphan Drug Act, Orphan Drug Tax Credit
NORD submits comments on FDA Draft Guidance on Interpreting Sameness for Gene Therapy Products Under the Orphan Drug Regulations
Published: Jul 28, 2020
Tagged in: Gene Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act
